Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
The centre has an initial capacity of 500 FTEs
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Expertise in exosomes isolation and characterization will drive innovation in this field
The NFI is published to promote the rational use of medicines in the country.
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Subscribe To Our Newsletter & Stay Updated
